 "Gufic Biosciences receives patents for two formulations in India")
Gufic Biosciences has received patents from the Intellectual Property India, The Patent Office, Government of India, for two formulations - parental formulation of anidulafungin and a freeze dried parental composition of tigecycline.
Anidulafungin is a semisynthetic echinocandin used as an antifungal drug. On the other hand, tigecycline, a glycylcycline that is administered intravenously, is an antibiotic used to treat a number of bacterial infections.
The company said that it was in the process of applying patents for the two formulations in other countries as well.
Gufic Group manufactures pharmaceutical and herbal products along with a wide range of APIs. It is one of the leading manufacturers of lyophilised injections in India and makes lyophilised products such as antibiotic, antifungal, cardiac, infertility, antiviral and proton-pump inhibitor segments.
Gufic group has three facilities in India - at Navsari & Vadodara in Gujarat and Belgaum in Karnataka - and one production plant in Uzbekistan. Navsari is the group’s lyophilised formulation, API and herbal manufacturing facility. While Vadodara plant manufactures personal hygiene product, its herbal formulation manufacturing facility is located at Belgaum.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%